Overview of emerging treatment of non-alcoholic fatty liver disease: more than one drug needed? by 諛뺤��슜
© HepatoBiliary Surgery and Nutrition. All rights reserved.   HepatoBiliary Surg Nutr 2019;8(5):522-524 | http://dx.doi.org/10.21037/hbsn.2019.05.08
Non-alcoholic fatty liver disease (NAFLD) comprises 
isolated hepatic steatosis, non-alcoholic steatohepatitis 
(NASH), liver failure-associated complications of liver 
cirrhosis, and liver cancer. These are forecasted to be the 
leading liver diseases in the future. Identifying patients 
with NAFLD at highest risk for developing clinically 
meaningful outcomes is a key issue for managing therapy in 
those with NAFLD. Because fibrosis stage is a marker for 
determining clinical outcomes (1), it should be considered 
the most important treatment parameter. Generally, NASH 
patients without fibrosis are regarded to have a low risk 
of NAFLD-associated complications (2). NASH patients 
with no fibrosis (F0) or negligible fibrosis (F1) has an 
excellent prognosis; close follow-up and treatments are 
not requisite. However, the risks of liver-associated illness 
and death increase dramatically once bridging fibrosis 
(F3) or cirrhosis (F4) occurs in NAFLD, justifying much 
closer follow-up and monitoring to determine the long-
term overall mortality from liver disease in these patients 
compared with those with little or no fibrosis (3,4). Thus, 
it is crucial for clinicians to identify patients who have 
progressed to advanced NAFLD and classify them by 
severity of liver disease. For diagnosing and determining 
the severity of NAFLD and evaluating fibrosis, liver 
biopsy still remains the gold standard. However, there are 
many shortcomings in liver biopsy, including subjectivity 
of observer interpretation, high cost, and sample error. 
Because of these, many non-invasive methods using scoring 
systems, imaging tools, and various serum biomarkers have 
been tried as substitutes for liver biopsy and to subdivide 
NAFLD patients into different prognosis categories. For 
example, magnetic resonance elastography and Fibroscan® 
(Echosens, France), which are elastography-based methods, 
can be considered, although these have not yet been 
approved for this indication (5,6). Even though optimal 
non-invasive diagnostic tools are still debated, clinicians 
should keep the importance of selecting high-risk patients 
in mind. 
The primary approaches for NAFLD treatment are 
control of comorbid metabolic illnesses and lifestyle 
modifications, which are important for all patients. Also, 
a stage-based treatment approach should be considered. 
Most patients do not need pharmacological treatment, 
given the low likelihood of adverse liver-related outcomes 
in low-risk NAFLD patients. However, management is 
tailored according to the severity of fibrosis for patients 
who have more significant fibrosis (F2 or higher) when 
NASH is diagnosed. Nevertheless, the actual options for 
NASH treatment are restricted due to high individual 
variability and the rather complex nature of the disease. 
In a recent issue, Friedman et al. widely reviewed the 
potential candidate-drugs under evaluation in pre-clinical 
studies as well as those currently used to treat NAFLD in 
clinical practice (7). Unfortunately, none of the approaches-
metabolic targeted therapies, anti-apoptotic agents, anti-
inflammatory or anti-fibrotic targeted therapies, and 
extrahepatic targeted therapies—have provided clear 
results even though many clinical trials are underway. The 
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key challenge for clinicians that are waiting for new and 
effective therapy approvals is to understand the spectrum of 
liver disease in the context of disease progression. Several 
factors that promote inflammation, for example, visceral 
adiposity, changes in intestinal microbiota, and metabolic 
syndrome, increase hepatocyte exposure to cytokines, gut-
derived products, and other hepatotoxic inflammatory 
mediators. Several molecular pathways contribute to the 
development of NAFLD, and the mechanisms that lead to 
disease and clinical manifestations are highly heterogeneous. 
In clinical trials, dozens of medications are currently being 
tested to address these mechanisms (8). The therapies are 
diverse in their mechanisms of action which are currently 
focused on anti-inflammatory effects, anti-fibrotic effects, 
or metabolic targets. Among them, this editorial focuses 
on four medications that are emerging as pharmacological 
options in phase III clinical trials: cenicriviroc (CVC), 
elafibranor, selonsertib (SEL), and obeticholic acid (OCA). 
CVC, a dual CCR2/5 (chemokine receptor 2 and 5) 
antagonist, demonstrated anti-fibrotic effects in preclinical 
models. NASH patients with fibrosis were treated with CVC 
(150 mg/day or placebo) for 24 months and histological 
improvement was evaluated in the phase IIb clinical trial. 
Analysis of a secondary endpoint, achieving a ≥1-stage 
improvement in fibrosis, indicated that a greater number of 
patients in the CVC group (20%) achieved an improvement 
in fibrosis compared with the placebo group (10%) 
(P value =0.02), even though the difference in histological 
improvement was not meaningful between the placebo 
group (19%) and the CVC groups (16%), respectively 
(P value =0.52) (9). A phase III RCT is currently underway 
to see the effects of CVC (150 mg/day or placebo) on 
NAFLD patients with liver fibrosis (AURORA). The 
second category, elafibranor is a peroxisome proliferator-
activated receptor alpha/delta (PPAR-α/β) agonist. Daily 
administration of the dual PPAR α/β agonist elafibranor 
(80 mg) in obese subjects is associated with improved 
peripheral and hepatic insulin resistance (10). A recent 
randomized clinical trial showed that a daily oral dose 
of 120 mg elafibranor for 52 weeks was associated with 
improvements in hepatic steatosis and fibrosis (11). 
Currently, the phase III RCT is underway to rate the effects 
of elafibranor (120 mg/day) on histological improvement, 
liver-related complications, drug-related mortality, and 
cardiovascular disease at 72 weeks.
Third, SEL (GS-4997) is a selective apoptosis signal-
regulating kinase 1 (ASK1) inhibitor. To assess the effects 
of SEL (18, 6 mg/day, placebo), two phase III studies 
have been started for NASH patients with compensated 
cirrhosis (STELLAR-4) or bridging fibrosis (STELLAR-3) 
to assess histological improvement with a planned analysis 
at 48 weeks. Unfortunately, both the STELLAR-3 and 
STELLAR-4 study failed to show a significant benefit in 
patients receiving the drug compared with the placebo 
group in the outcome of the week 48 analysis. Although 
these results are disappointing, additional sub-analyses 
of patients who responded optimally in the STELLAR 
program can be considered. Farnesoid X receptors (FXRs), 
are nuclear receptor transcription factors expressed in the 
liver that play a role in lipid metabolism. Interestingly, 
loss of FXR expression in mice amplified the ability 
of endoplasmic reticulum stress to drive expression of 
NACHT, LRR, PYD domain-containing protein 3 
(NLRP3), and thioredoxin interacting protein, thereby 
augmenting liver injury. However, the FXR ligand had the 
opposite effect. FXR activation reduced the expression of 
NLRP3 by inhibiting the endoplasmic reticulum stress-
mediated PERK/CHOP pathway. These results indicate 
that FXR regulation of endoplasmic reticulum stress helps 
inhibit the liver injury associated with activation of the 
inflammasome (12). A phase III clinical trial is currently 
enrolling biopsy-proven NASH patients to see the effect 
of OCA (25, 10 mg/day, placebo) on liver histology for 72 
weeks. To assess long-term outcomes including progression 
to cirrhosis, death, or need for liver transplantation, those 
patients will be followed for 6 years. 
Based on these phase III clinical studies, it is expected 
that a treatment agent for NASH will emerge in the 
future. Although the results of these phase III studies are 
pending, less than 40% of overall patients responded to the 
clinical trial agents. Considering that numerous molecular 
pathways interact to orchestrate the pathogenesis of NASH, 
combined therapies are likely to be utilized in the future. As 
each drug will likely target different aspects of pathogenesis, 
it is hard to predict which combined therapies will be most 
effective; for example, a drug targeting de novo lipogenesis 
combined with an anti-inflammatory agent or a drug that 
improves lipid metabolism paired with an anti-fibrotic 
agent.
It is also important to consider how genetic variations 
in the host influence disease phenotype. A genetic 
predisposition to NAFLD has been described in several 
studies (13). Patatin-like phospholipase domain-containing 
protein 3 (PNPLA3), which encodes the adiponutrin 
protein, identified by a genome-wide association study 
(GWAS), was the first gene implicated in NAFLD. 
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Subsequent GWASs have verified and characterized 
several other variants with moderate effect sizes, including 
variants in GCKR, HSD17B13, TM6SF2, and MBOAT7. 
It is important to identify the genetic factors that regulate 
susceptibility to liver damage because studies in twins have 
indicated that heritable factors account for approximately 
half of the inter-individual differences in the prevalence of 
NASH with cirrhosis (14). 
In summary, easily accessible non-invasive modalities 
to accurately diagnose and assess fibrosis associated 
with NAFLD are needed to determine treatments in 
clinical practice. Despite the exciting development of 
new pharmacological agents, it is also important to 
consider the value of researching new target molecules 
such as gut-derived serotonin (15) or combined therapies 
as treatment options, especially considering that many 
molecular pathways and numerous genetic, epigenetic, 
and environmental factors contribute to individual disease 
phenotypes.
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